NCT07314060

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.

Conditions

• Generalized Pustular Psoriasis

Interventions

Type	Name	Description
DRUG	TQH2929 Injections	TQH2929 is a humanized monoclonal antibody that interfering with the signal cascade.
DRUG	TQH2929 Placebo	Placebo contains no active substance.

Timeline

• Start date: 2026-03-19
• Primary completion: 2026-12-01
• Completion: 2027-07-01
• First posted: 2026-01-02
• Last updated: 2026-03-24

Locations

32 sites across 1 country: China